3.46
+0.09(+2.67%)
Currency In USD
| Previous Close | 3.37 |
| Open | 3.43 |
| Day High | 3.55 |
| Day Low | 3.37 |
| 52-Week High | 4.68 |
| 52-Week Low | 1.75 |
| Volume | 97,556 |
| Average Volume | 63,267 |
| Market Cap | 48.9M |
| PE | -6.53 |
| EPS | -0.53 |
| Moving Average 50 Days | 3.2 |
| Moving Average 200 Days | 2.96 |
| Change | 0.09 |
If you invested $1000 in Grace Therapeutics, Inc. (GRCE) since IPO date, it would be worth $1,149.5 as of January 01, 2026 at a share price of $3.46. Whereas If you bought $1000 worth of Grace Therapeutics, Inc. (GRCE) shares 1 year ago, it would be worth $1,149.5 as of January 01, 2026 at a share price of $3.46.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference
GlobeNewswire Inc.
Nov 17, 2025 1:00 PM GMT
PRINCETON, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being d
Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting
GlobeNewswire Inc.
Nov 11, 2025 1:30 PM GMT
STRIVE-ON Results Accepted for Late-Breaking PresentationPRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-s
Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review
GlobeNewswire Inc.
Oct 23, 2025 12:00 PM GMT
PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being d